NCT06129084Active, not recruiting
A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing
ctDNA-FGFR Status as a Predictive Biomarker for FGFR Targeted Therapy
Source: ClinicalTrials.gov · Last updated 15 Dec 2025
Brief summary (registry, in English)
A new drug, erdafitinib, became available for some patients with bladder cancer that has spread to other organs. To qualify, patients must have specific genetic changes in their tumors. Currently, doctors use tumor tissue samples to check for these genetic changes, but these samples might not accurately reflect the current state of the patient's cancer. In this study, Investigators will test the patient's blood for these genetic changes in addition to the tumor tissue samples. It is thought that the blood test will give a more accurate result. Investigators hope this study will help to find out if more patients can benefit from erdafitinib than the ones identified by tissue testing only.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 260 (actual)
- First submitted
- 8 Nov 2023
- Start date
- 11 Jan 2021
- Primary completion date
- 15 Sept 2025
- Lead sponsor
- Bernie Eigl
- Diseases
- Bladder cancer
- NCT number
- NCT06129084
What you commit to
- Study type: Observational
- Participants enrolled: 260
- From 11 Jan 2021 to the primary completion date, 15 Sept 2025
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Metastatic bladder cancer patients who will not have tissue sent for FGFR testing will be excluded from this study.
Who the study is looking for
- Patients with metastatic bladder cancer who are about to undergo tissue testing for FGFR mutations and who have blood samples drawn during the management of their disease are eligible to be included in this analysis.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Arthur J.E. Child Comprehensive Cancer Centre Coordinator of this site? Confirm its status | Calgary | Canada | Unknown status |
| Cross Cancer Institute Coordinator of this site? Confirm its status | Edmonton | Canada | Unknown status |
| London Health Sciences Centre Coordinator of this site? Confirm its status | London | Canada | Unknown status |
| Ottawa Hospital Research Institute Coordinator of this site? Confirm its status | Ottawa | Canada | Unknown status |
| CHU de Quebec-Universite Laval Coordinator of this site? Confirm its status | Québec | Canada | Unknown status |
| Princess Margaret Cancer Centre Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
| BC Cancer Agency Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.